Research Article
H-Y Antigen Incompatibility Not Associated with Adverse Immunologic Graft Outcomes: Deceased Donor Pair Analysis of the OPTN Database
Table 1
Patient characteristics.
| | Donor male: recipient male () | Donor male: recipient female () | P value |
| | Recipient characteristics | | | | | Mean age | | | 0.05 | | Race/ethnicity | | | 0.061 | | Caucasian | 50.4% | 49.2% | | | African American | 29.8% | 30.4% | | | Hispanic | 13.6% | 13.6% | | | Other | 6.2% | 6.9% | | | Mean BMI | | | 0.13 | | Cause of endstage renal disease | | | <0.001 | | Diabetes Mellitus | 24.0% | 21.8% | | | Glomerulonephritis | 16.8% | 16.7% | | | Hypertension | 22.3% | 17.2% | | | Other/unknown | 29.7% | 34.9% | | | Polycystic kidney disease | 7.3% | 9.3% | | | Duration of dialysis prior to transplant | | | 0.021 | | Preemptive | 8.8% | 10.1% | | | <1 Year | 10.1% | 9.7% | | | 1 to 2 Years | 15.8% | 15.9% | | | 2 to 3 Years | 15.2% | 15.0% | | | 3 to 4 Years | 13.7% | 13.4% | | | 4 to 5 Years | 10.4% | 9.6% | | | More than 5 Years | 20.8% | 20.9% | | | On dialysis at transplant duration unknown | 4.8% | 4.9% | | | Dialysis status not recorded | .4% | .5% | | | Previous transplant | 13.2% | 13.0% | 0.69 | | Previous pregnancy | | | | | Yes | NA | 60.1% | | | No | NA | 25.0% | | | Not recorded | NA | 14.9% | | | PRA | | | <0.001 | | 0% | 73.9% | 62.3% | | | 1–79% | 23.2% | 30.7% | | | 80–100% | 2.9% | 7.0% | | | Donor recipient CMV serology | | | <0.001 | | Donor +/recipient − | 15.6% | 12.1% | | | Donor + or −/recipient + | 51.0% | 57.2% | | | Donor −/recipient − | 7.3% | 5.6% | | | Missing donor or recipient serology | 26.0% | 25.1% | | | Mean HLA mismatch | | | 0.56 | | Cold ischemia time | | | 0.22 | | 0–12 Hours | 21.7% | 20.7% | | | 12–24 Hours | 48.7% | 48.9% | | | 24–36 Hours | 17.1% | 17.6% | | | >36 Hours | 2.9% | 2.8% | | | Not recorded | 9.6% | 10.1% | | | Delayed graft function | | | <0.001 | | Yes | 27.0% | 21.9% | | | No | 72.8% | 77.9% | | | Not recorded | 0.2% | 0.2% | | | Induction therapy | | | <0.001 | | Lymphocyte depleting antibody | 40.8% | 43.3% | | | Interleukin 2 receptor antagonist | 26.1% | 24.3% | | | Other/None | 33.1% | 32.4% | | | Discharge maintenance immunosuppression | | | <0.001 | | Tacrolimus: MPA Agent | 53.4% | 54.9% | | | Cyclosporine: MPA Agent | 22.8% | 21.3% | | | Tacrolimus or Cyclosporine: azathioprine | 3.5% | 3.8% | | | mTOR any combination | 9.0% | 8.1% | | | Tacrolimus or cyclosporine alone | 5.1% | 4.9% | | | Other combination | 6.2% | 7.0% | | | Discharge maintenance steriods | | | 0.82 | | No | 13.1% | 12.9% | | | Yes | 81.2% | 81.5% | | | Not specified | 5.7% | 5.6% | |
|
|
